GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Purple Biotech PPBT.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

1.00

—

Close of 26 Oct 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Purple Biotech

Its shares trade on Tel Aviv under the ticker PPBT.TA. It has been listed since 3 September 1978. In the fiscal year to 31 December 2019, it reported revenue of $1.0m and a net loss of $5.8m. At that date it held total assets of $14.7m and shareholders' equity of $10.4m.

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Sept 1978
Employees
13

Leadership

Pay as last reported

  • Dr. Eric RowinskyChairman of the Board, since 2019
  • Mr. Itzhak IsraelChief Executive Officer & Director, since 2012
  • Mr. Gil EfronDeputy Chief Executive Officer, Chief Financial Officer
  • Dr. Gil Ben-MenachemVice President - Business Development
  • Mr. Avraham Ben-TzviGeneral Counsel, Secretary
  • Mr. Yisrael GewirtzInternal Auditor
  • Dr. Bertrand LiangChief Medical Officer
  • Dr. Hadas ReuveniFounder and Chief Technology Officer of TyrNovo (a subsidiary)
  • Dr. Michael SchicklerHead of Clinical Operations
  • Mr. Robert GagnonDirector
  • Ms. Suzana Nahum-ZilberbergDirector
  • Mr. Simcha RockDirector, since 2013

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Purple Biotech Ltd. develops NT-219 and CM-24 for cancer resistance pathways.
  • Consensi combines celecoxib and amlodipine besylate for osteoarthritis and hypertension.
  • The company has 13 employees focused on pharmaceutical development.

Weaknesses

  • Purple Biotech Ltd. is a development stage company with limited resources.
  • The firm has no listed products beyond NT-219, CM-24, and Consensi.
  • Rehovot city has no direct impact on the company's pharmaceutical development.

Opportunities

  • The Health Care sector offers growth for new cancer treatments like NT-219.
  • Pharmaceutical industry advancements support monoclonal antibody development.
  • Consensi's fixed-dose combination could expand in the osteoarthritis market.

Threats

  • Purple Biotech Ltd. faces competition in the Health Care sector.
  • The company's development stage status may delay product launches.
  • Financials in the pharmaceutical industry require significant investment.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.